Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. More Details
Second-rate dividend payer with mediocre balance sheet.
Share Price & News
How has Becton Dickinson's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: BDX is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: BDX's weekly volatility (3%) has been stable over the past year.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: BDX underperformed the US Medical Equipment industry which returned 20.5% over the past year.
Return vs Market: BDX underperformed the US Market which returned 21% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Becton Dickinson's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall StDoes Becton, Dickinson and Company's (NYSE:BDX) Weak Fundamentals Mean That The Market Could Correct Its Share Price?
2 weeks ago | Simply Wall StWhat Type Of Shareholders Make Up Becton, Dickinson and Company's (NYSE:BDX) Share Registry?
4 weeks ago | Simply Wall StDoes Becton Dickinson (NYSE:BDX) Have A Healthy Balance Sheet?
Is Becton Dickinson undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: BDX ($257.77) is trading below our estimate of fair value ($271.36)
Significantly Below Fair Value: BDX is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: BDX is poor value based on its PE Ratio (93.8x) compared to the US Medical Equipment industry average (54.1x).
PE vs Market: BDX is poor value based on its PE Ratio (93.8x) compared to the US market (21.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BDX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BDX is good value based on its PB Ratio (3.1x) compared to the US Medical Equipment industry average (5x).
How is Becton Dickinson forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual revenue growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if BDX's forecast earnings growth is above the savings rate (2%).
Earnings vs Market: Insufficient data to determine if BDX's earnings are forecast to grow faster than the US market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: BDX's revenue (5.5% per year) is forecast to grow slower than the US market (10.2% per year).
High Growth Revenue: BDX's revenue (5.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BDX's Return on Equity is forecast to be low in 3 years time (14.9%).
How has Becton Dickinson performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BDX has a large one-off loss of $1.0B impacting its September 30 2020 financial results.
Growing Profit Margin: BDX's current net profit margins (4.5%) are lower than last year (6.2%).
Past Earnings Growth Analysis
Earnings Trend: BDX's earnings have declined by 3% per year over the past 5 years.
Accelerating Growth: BDX's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BDX had negative earnings growth (-28.8%) over the past year, making it difficult to compare to the Medical Equipment industry average (-0.3%).
Return on Equity
High ROE: BDX's Return on Equity (3.7%) is considered low.
How is Becton Dickinson's financial position?
Financial Position Analysis
Short Term Liabilities: BDX's short term assets ($9.0B) exceed its short term liabilities ($5.8B).
Long Term Liabilities: BDX's short term assets ($9.0B) do not cover its long term liabilities ($24.4B).
Debt to Equity History and Analysis
Debt Level: BDX's debt to equity ratio (75.5%) is considered high.
Reducing Debt: BDX's debt to equity ratio has reduced from 178.9% to 75.5% over the past 5 years.
Debt Coverage: BDX's debt is not well covered by operating cash flow (19.7%).
Interest Coverage: BDX's interest payments on its debt are well covered by EBIT (4.8x coverage).
What is Becton Dickinson current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BDX's dividend (1.29%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.38%).
High Dividend: BDX's dividend (1.29%) is low compared to the top 25% of dividend payers in the US market (3.84%).
Stability and Growth of Payments
Stable Dividend: BDX's dividends per share have been stable in the past 10 years.
Growing Dividend: BDX's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its high payout ratio (114.9%), BDX's dividend payments are not well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: BDX's dividends in 3 years are forecast to be well covered by earnings (29.1% payout ratio).
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Tom Polen (47 yo)
Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer and Director at Becton, Dickinson and Company since January 28, 2020. Mr. Polen has been President of Becton, Dickinson and Co...
CEO Compensation Analysis
Compensation vs Market: Tom's total compensation ($USD11.67M) is about average for companies of similar size in the US market ($USD10.54M).
Compensation vs Earnings: Tom's compensation has increased by more than 20% whilst company earnings have fallen more than 20% in the past year.
|Executive Chairman||8.5yrs||US$3.21m||0.081% |
|Executive VP||7.5yrs||US$4.92m||0.0086% |
|Executive VP of Regulatory & Government Affairs and General Counsel||3.08yrs||US$3.94m||0.0020% |
|Executive VP & President of the Medical Segment||4.25yrs||US$3.72m||0.0037% |
|Executive VP & President of the Life Sciences Segment||2.67yrs||US$4.16m||0% |
|VP, Controller & Chief Accounting Officer||1.25yrs||no data||0.00045% |
|Senior VP of Corporate Finance||2.5yrs||no data||0.00072% |
|Executive VP of Research & Development and CTO||2.58yrs||no data||no data|
|Executive VP of Global Services & Chief Information Officer||no data||no data||no data|
|Senior Vice President of Investor Relations||no data||no data||no data|
|Senior VP and Chief Ethics & Compliance Officer||no data||no data||no data|
Experienced Management: BDX's management team is considered experienced (2.6 years average tenure).
|Executive Chairman||8.5yrs||US$3.21m||0.081% |
|Independent Lead Director||6yrs||US$382.07k||0.0031% |
|Independent Director||4.33yrs||US$322.07k||0.0012% |
|Independent Director||4yrs||US$322.07k||0.027% |
|Independent Director||10.5yrs||US$347.07k||0.0046% |
|Independent Director||18.33yrs||US$342.07k||0.0075% |
|Independent Director||6.83yrs||US$322.07k||0.0021% |
|Independent Director||8.5yrs||US$317.07k||0.0021% |
|Independent Director||8yrs||US$347.07k||0.0020% |
|Independent Director||14.17yrs||US$347.07k||0.00076% |
|Independent Director||4yrs||US$322.07k||0.00094% |
Experienced Board: BDX's board of directors are considered experienced (7.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.3%.
Becton, Dickinson and Company's company bio, employee growth, exchange listings and data sources
- Name: Becton, Dickinson and Company
- Ticker: BDX
- Exchange: NYSE
- Founded: 1897
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: US$74.973b
- Shares outstanding: 290.85m
- Website: https://www.bd.com
Number of Employees
- Becton, Dickinson and Company
- 1 Becton Drive
- Franklin Lakes
- New Jersey
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|BDX||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Jan 1968|
|BOX||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jan 1968|
|BOX||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Jan 1968|
|BDX||SWX (SIX Swiss Exchange)||Yes||Common Stock||CH||CHF||Jan 1968|
|0R19||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Jan 1968|
|BDX *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Jan 1968|
|BDX||WBAG (Wiener Boerse AG)||Yes||Common Stock||AT||EUR||Jan 1968|
|BOX||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Jan 1968|
|B1DX34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 5 REPR 1 COM||BR||BRL||Jan 2020|
|BDXB||NYSE (New York Stock Exchange)||6% DP CONV PFD B||US||USD||May 2020|
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company’s BD Medical segment offers peripheral intrav...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/01/14 23:40|
|End of Day Share Price||2021/01/14 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.